As for branded products, Merck’s (NYSE:MRK) cancer blockbuster dominates the list, and the checkpoint inhibitor is on track to generate peak sales in 2025, Evaluate Pharma projects. The New ...

Pharma is missing opportunities to ... market research, sales aid materials and the occasional global website. ‘The rest’, including all sales and promotional activities, is left to the ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.9% year on year to $17.76 billion. On the other hand, the company ...

Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

The Pharmaceutical R&D Outsourcing Market was valued at USD 84.01 billion in 2023, and is expected to reach USD 150.04 billion by 2029, rising at a CAGR of 10.15% The global pharmaceutical R&D ...

Japan’s Mitsubishi Chemical Group has resolved, at a meeting of the board of directors held today, to transfer its consolidated subsidiary, Mitsubishi Tanabe Pharma (MTPC), which engages in the ...

Its high-margin global specialty pharmaceutical segment, which includes medicines for conditions such as alopecia and psoriasis, reported a 17.5% jump in sales to $370 million, or 21% of total sales.

President Donald Trump has halted all US foreign assistance, barring to Israel and Egypt, for at least 90 days to review all ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...